Details of Drug-Drug Interaction
| Drug General Information (ID: DDIBYAFMZG) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Defibrotide | Drug Info | Selumetinib | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antiviral Agents | Multikinase Inhibitors | |||||||
| Structure | |||||||||
| Mechanism of Defibrotide-Selumetinib Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Increased risk of bleeding Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Defibrotide | Selumetinib | |||||||
| Mechanism |
Risk of bleeding Anticoagulant |
Risk of bleeding Antiplatelet/anticoagulant effects |
|||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Bleeding | ||||||||
| Factor Description | Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Close clinical and laboratory observation for hematologic complications may be appropriate when selumetinib is initiated in patients stabilized on anticoagulant or antiplatelet therapy. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. | ||||||||